Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDA NASDAQ:BHST NASDAQ:CNTX NASDAQ:TLPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$1.17-2.5%$1.02$0.78▼$2.45$13.65M0.441.45 million shs250,151 shsBHSTBioHarvest Sciences$2.89+0.7%$3.56$2.74▼$12.80$56.30M0.8720,408 shs60,344 shsCNTXContext Therapeutics$0.64-2.5%$1.74$0.55▼$3.62$60.06M1.754.06 million shs1.51 million shsTLPHTalphera$1.18+10.3%$0.90$0.38▼$1.57$55.53M0.7264,014 shs874,606 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia-2.50%-3.31%+13.59%-1.68%-44.55%BHSTBioHarvest Sciences+0.70%+3.58%-9.40%-32.95%-58.12%CNTXContext Therapeutics-2.46%+10.48%-63.57%-75.66%-2.66%TLPHTalphera+10.28%+12.38%+52.26%+49.05%+153.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$1.17-2.5%$1.02$0.78▼$2.45$13.65M0.441.45 million shs250,151 shsBHSTBioHarvest Sciences$2.89+0.7%$3.56$2.74▼$12.80$56.30M0.8720,408 shs60,344 shsCNTXContext Therapeutics$0.64-2.5%$1.74$0.55▼$3.62$60.06M1.754.06 million shs1.51 million shsTLPHTalphera$1.18+10.3%$0.90$0.38▼$1.57$55.53M0.7264,014 shs874,606 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia-2.50%-3.31%+13.59%-1.68%-44.55%BHSTBioHarvest Sciences+0.70%+3.58%-9.40%-32.95%-58.12%CNTXContext Therapeutics-2.46%+10.48%-63.57%-75.66%-2.66%TLPHTalphera+10.28%+12.38%+52.26%+49.05%+153.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 2.00Hold$25.002,036.75% UpsideBHSTBioHarvest Sciences 2.00Hold$10.00246.02% UpsideCNTXContext Therapeutics 2.89Moderate Buy$6.17867.17% UpsideTLPHTalphera 2.25Hold$3.00154.24% UpsideCurrent Analyst Ratings BreakdownLatest BCDA, BHST, TLPH, and CNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/16/2026CNTXContext Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $4.006/9/2026BCDABioCardia HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/8/2026TLPHTalphera Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/5/2026TLPHTalphera HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.006/3/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/30/2026TLPHTalphera Westpark CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.004/20/2026BCDABioCardia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026TLPHTalphera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$60K221.91N/AN/A$0.08 per share14.63BHSTBioHarvest Sciences$35.16M1.61N/AN/A$1.30 per share2.22CNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/ATLPHTalphera$30K2,041.40N/AN/A$0.37 per share3.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$8.23M-$0.91N/AN/AN/AN/A-5,456.14%-232.75%8/10/2026 (Estimated)BHSTBioHarvest Sciences-$11.14M-$0.59N/AN/AN/A-32.54%-76.03%-25.30%8/10/2026 (Estimated)CNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%8/5/2026 (Estimated)TLPHTalphera-$14.29M-$0.31N/AN/AN/AN/A-92.98%-53.22%8/13/2026 (Estimated)Latest BCDA, BHST, TLPH, and CNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BCDABioCardia-$0.17-$0.21-$0.04-$0.21N/AN/A5/14/2026Q1 2026BHSTBioHarvest Sciences-$0.13-$0.11+$0.02-$0.11$8.50 million$8.51 million5/13/2026Q1 2026TLPHTalphera-$0.07-$0.04+$0.03-$0.04N/AN/A5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/ABHSTBioHarvest SciencesN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.410.41BHSTBioHarvest Sciences0.032.962.44CNTXContext TherapeuticsN/A8.968.96TLPHTalpheraN/A5.305.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%BHSTBioHarvest SciencesN/ACNTXContext Therapeutics14.03%TLPHTalphera37.67%Insider OwnershipCompanyInsider OwnershipBCDABioCardia17.40%BHSTBioHarvest SciencesN/ACNTXContext Therapeutics4.80%TLPHTalphera3.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia4011.38 million9.40 millionOptionableBHSTBioHarvest SciencesN/A19.62 millionN/AN/ACNTXContext Therapeutics791.88 million87.47 millionNot OptionableTLPHTalphera1951.90 million50.08 millionOptionableBCDA, BHST, TLPH, and CNTX HeadlinesRecent News About These CompaniesTalphera (NASDAQ:TLPH) Trading Up 1.9% - Still a Buy?July 3, 2026 | americanbankingnews.comTalphera (TLPH) CEO Angotti buys $85k in sharesMay 21, 2026 | investing.comTalphera Earnings Call Highlights NEPHRO Trial MomentumMay 19, 2026 | tipranks.comTalphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...May 15, 2026 | finance.yahoo.comTalphera Earnings Call Highlights Trial Momentum, RisksMay 14, 2026 | tipranks.comTalphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 14, 2026 | finanznachrichten.deTalphera, Inc. (TLPH) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comTalphera Q1 2026 Earnings Call TranscriptMay 13, 2026 | finance.yahoo.comTalphera targets Niyad PMA filing in 2026 and potential approval in 2027 as NEPHRO enrollment surpasses 50%May 13, 2026 | seekingalpha.comTalphera (TLPH) Q1 2026 Earnings TranscriptMay 13, 2026 | fool.comTalphera Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | prnewswire.comTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026May 7, 2026 | prnewswire.comWestPark Capital initiates coverage of Talphera (TLPH) with buy recommendationMay 1, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC), Talphera (TLPH) and Abivax SA Sponsored ADR (ABVX)March 26, 2026 | theglobeandmail.comTalphera (NASDAQ:TLPH) CEO Acquires $125,852.90 in StockMarch 26, 2026 | insidertrades.comTalphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026March 25, 2026 | prnewswire.comTalphera, Inc.: Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 24, 2026 | finanznachrichten.deTalphera, Inc. (TLPH) Analyst/Investor Day TranscriptMarch 24, 2026 | seekingalpha.comTalphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 23, 2026 | prnewswire.comTalphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026March 18, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCDA, BHST, TLPH, and CNTX Company DescriptionsBioCardia NASDAQ:BCDA$1.17 -0.03 (-2.50%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.77%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.BioHarvest Sciences NASDAQ:BHST$2.89 +0.02 (+0.70%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$2.92 +0.03 (+1.04%) As of 07/6/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Context Therapeutics NASDAQ:CNTX$0.64 -0.02 (-2.46%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$0.66 +0.02 (+3.04%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Talphera NASDAQ:TLPH$1.18 +0.11 (+10.28%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$1.16 -0.02 (-1.69%) As of 07/6/2026 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
